Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation

Aim: The selective BRAF and MEK inhibitors (BRAFi+MEKi) have substantially improved the survival of melanoma patients with BRAF V600 mutations. However, BRAFi+MEKi can also cause severe or fatal outcomes. We aimed to identify and compare serious adverse events (sAEs) that are significantly associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Meirson, Tomer, Asher, Nethanel, Bomze, David, Markel, Gal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352287/
https://www.ncbi.nlm.nih.gov/pubmed/32580351
http://dx.doi.org/10.3390/cancers12061650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352287/
https://www.ncbi.nlm.nih.gov/pubmed/32580351
http://dx.doi.org/10.3390/cancers12061650

Ejemplares similares